Chris Mirabelli

Chris K.
Mirabelli is the founder of Ionis Pharmaceuticals, Inc., founded in 1989, where the title held was Senior Vice President-Research from 1989 to 1993.
Current jobs include Executive Chairman at Flamingo Therapeutics BV; Director at Theraclone Sciences, Inc., Galleon Pharmaceuticals, Inc., Visionary Therapeutics Corp., Fredonia College Foundation, and Cypherpunk Technologies, Inc. (title starting 2025); Managing Director at Healthcare Partners VIII LLC, Healthcare Partners IX LLC, Healthcare Strategic Partners, LLC, and HealthCare Ventures LLC (title starting 2000); Director at Aro Biotherapeutics Co. (title starting 2020); and Trustee at Guilford College.
Former jobs include Chairman, President & Chief Executive Officer at LeukoSite, Inc. from 1993 to 1999; Chief Executive Officer & Director at Anexon, Inc. from 2012 to 2014; Chairman at Thios Pharmaceuticals, Inc. and Proteostasis Therapeutics, Inc. (2010–2016); Director, President-Pharmaceutical R&D at Millennium Pharmaceuticals, Inc. from 1999 to 2000; Director at Critical Therapeutics, Inc. from 2001 to 2008; Director at FoldRx Pharmaceuticals LLC, Anchor Therapeutics, Inc., Antisoma, Inc., and Dynacure SA (Member-Supervisory Board); President & Director at DecImmune Therapeutics, Inc.; Independent Director at Trevena, Inc. from 2013 to 2014; President at Adheron Therapeutics, Inc.; and Principal at SmithKline & French SpA. Education includes an undergraduate degree from The State University of New York College at Fredonia in 1977 and a doctorate from Baylor College of Medicine in 1981.